



Press Release

TxCell: monthly information regarding the total number of voting rights and the total number of shares

Valbonne, France, January 4, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, today reports the monthly information regarding the total number of voting rights and the total number of shares.

Pursuant to the article 223-16 of the AMF General Regulation, the total number of shares comprising the share capital and the total number of voting rights as of December 31, 2015, is presented as follow:

Date	Total number of shares of the Company	Total number of voting rights	
		Total gross (1)	Total net (2)
31/12/2015	12 887 326	12 887 326	12 871 046

(1) Pursuant to the article 223-11 of the AMF General Regulation, the total number of gross voting rights is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The number of gross voting rights (or theoretical voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

(2) The total number of net voting rights (or exercisable voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About TxCell: www.txcell.com

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell's lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 60 employees.

Contacts:

TxCell

Raphaël Flipo
CFO
Tél: +33 4 97 21 83 00
contact@txcell.com

NewCap

Financial Communication
Julien Perez / Pierre Laurent
Tél: +33 1 44 71 94 94
txcell@newcap.eu



Disclaimer:

This press release contains certain forward-looking statements concerning TxCell and its business. Such forward-looking statements are based on assumptions that TxCell considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of TxCell registered by the French Financial Markets Authority (*Autorité des marchés financiers*) on June 11, 2015 under number R. 15-049 and in the half year financial report of TxCell as of June 30, 2015 (a copy of which is available on www.txcell.com) and to the development of economic conditions, financial markets and the markets in which TxCell operates. The forward-looking statements contained in this press release are also subject to risks not yet known to TxCell or not currently considered material by TxCell. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of TxCell to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, TxCell shares in any country.